Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RLAY 
Relay Therapeutics Inc (RLAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: RLAY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.6
1 Year Target Price $13.6
| 6 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.38% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.23B USD | Price to earnings Ratio - | 1Y Target Price 13.6 |
Price to earnings Ratio - | 1Y Target Price 13.6 | ||
Volume (30-day avg) 13 | Beta 1.75 | 52 Weeks Range 1.77 - 7.64 | Updated Date 11/3/2025 |
52 Weeks Range 1.77 - 7.64 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.91 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.418 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -11011.37% |
Management Effectiveness
Return on Assets (TTM) -28.37% | Return on Equity (TTM) -46.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 277395560 | Price to Sales(TTM) 147.34 |
Enterprise Value 277395560 | Price to Sales(TTM) 147.34 | ||
Enterprise Value to Revenue 33.2 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 172411410 | Shares Floating 102553755 |
Shares Outstanding 172411410 | Shares Floating 102553755 | ||
Percent Insiders 1.36 | Percent Institutions 100.32 |
Upturn AI SWOT
Relay Therapeutics Inc
Company Overview
History and Background
Relay Therapeutics, founded in 2016, is a clinical-stage precision medicine company transforming the drug discovery process by combining advanced computational and experimental technologies. Its focus is on developing therapeutics for genetically defined cancers.
Core Business Areas
- Drug Discovery and Development: Relay Therapeutics focuses on discovering and developing novel protein kinase inhibitors targeting specific cancer-driving mutations.
- Dynamo Platform: The company leverages its Dynamo platform, integrating computational and experimental approaches to develop new medicines.
Leadership and Structure
Relay Therapeutics is led by a management team with experience in biotech and pharmaceutical industries. The organizational structure involves research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- RLY-4008 (estorasib): RLY-4008 is a highly selective, oral small molecule inhibitor of FGFR2. It is currently in clinical development for FGFR2-altered cholangiocarcinoma and other solid tumors. There isn't specific market share data publicly available at this stage of clinical development. Competitors: Incyte (Pemazyre), QED Therapeutics (Truseltiq) are competitors, but they are not as selective.
- RLY-2608: RLY-2608 is an investigational, oral, allosteric inhibitor of PI3Ku03b1. It is designed to target PI3Ku03b1-mutant breast cancer and other solid tumors. There isn't specific market share data publicly available at this stage of clinical development. Competitors: Novartis (alpelisib), Roche (taselisib).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in oncology, is driven by innovation and unmet needs. Precision medicine, focusing on genetically defined cancers, is a growing area.
Positioning
Relay Therapeutics is positioned as a precision medicine company leveraging computational and experimental approaches to develop targeted therapies. Its competitive advantage lies in its Dynamo platform and focus on specific mutations.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is substantial, estimated in the tens of billions of dollars. Relay Therapeutics is positioned to capture a share of this market by addressing specific, genetically-defined cancer subtypes.
Upturn SWOT Analysis
Strengths
- Proprietary Dynamo platform
- Experienced management team
- Focus on precision medicine
- Promising clinical pipeline
Weaknesses
- Reliance on clinical trial success
- High R&D costs
- Limited commercialized products
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships and collaborations
- Expansion of pipeline into new targets
- Potential for breakthrough therapies
- Growing demand for precision medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Patent expiration
Competitors and Market Share
Key Competitors
- INCY
- NVS
- ROSY
- LLY
Competitive Landscape
Relay Therapeutics competes with larger pharmaceutical companies with established oncology portfolios, as well as other biotech companies focused on precision medicine. Relay's Dynamo platform offers a potential competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Relay Therapeutics has experienced growth in its pipeline and platform capabilities since its founding.
Future Projections: Future growth is dependent on the success of its clinical trials and potential commercialization of its drug candidates. Analyst estimates vary based on pipeline projections.
Recent Initiatives: Recent initiatives include advancing RLY-4008 and RLY-2608 through clinical trials and expanding the pipeline through new target identification.
Summary
Relay Therapeutics is a promising precision medicine company with a novel drug discovery platform and a growing clinical pipeline. Its success hinges on the positive outcomes of ongoing clinical trials. Relay faces considerable risk inherent in drug development, but its innovative approach is attractive to investors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Relay Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions. Market share estimates are approximate and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relay Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-07-16 | CEO, President & Director Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 197 | Website https://www.relaytx.com |
Full time employees 197 | Website https://www.relaytx.com | ||
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.